This suggests that diabetes mellitus may lead to reduced serum AFP and PIVKA-II levels, potentially increasing the false-negative rate of AFP and PIVKA-II screening for HCC in T2DM patients. The gene discussed is AFP; the disease is hepatocellular carcinoma.